Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece

• Published in: Journal of chemotherapy (Florence) 2012-08, Vol.24 (4), p.191-194
• Main Authors: Galani, Irene, Souli, Maria, Daikos, George L, Chrysouli, Zoi, Poulakou, Garyphalia, Psichogiou, Mina, Panagea, Theofano, Argyropoulou, Athina, Stefanou, Ioanna, Plakias, George, Giamarellou, Helen, Petrikkos, George
• Format: Article
• Language: English
• Subjects: Amikacin - pharmacology; Aminoglycosides; Anti-Bacterial Agents - pharmacology; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antimicrobial Chemotherapy; Biological and medical sciences; Drug Resistance, Multiple, Bacterial; Enterobacter - drug effects; Enterobacter - isolation & purification; Enterobacter - metabolism; Enterobacteriaceae Infections - microbiology; Escherichia coli - drug effects; Escherichia coli - isolation & purification; Escherichia coli - metabolism; Escherichia coli Infections - microbiology; Gentamicins - pharmacology; Greece; Humans; Klebsiella Infections - microbiology; Klebsiella pneumoniae - drug effects; Klebsiella pneumoniae - isolation & purification; Klebsiella pneumoniae - metabolism; KPC; Medical sciences; Microbial Sensitivity Tests; Multidrug resistant; Pharmacology. Drug treatments; Sisomicin - analogs & derivatives; Sisomicin - pharmacology; Tertiary Care Centers; Tobramycin - pharmacology; VIM
• ISSN: 1120-009X; 1973-9478
• DOI: 10.1179/1973947812Y.0000000015

The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC 50 /MIC 90 to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs⩽4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC 50 and MIC 90 of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.